<!doctype html><html lang=cn><head><meta charset=utf-8><meta http-equiv=x-ua-compatible content="IE=edge"><meta name=viewport content="width=device-width,initial-scale=1"><meta name=referrer content="no-referrer"><link rel=dns-prefetch href=https://i.geekbank.cf/><title>机理综述｜姜黄的生物化学、安全性、药理活性和临床应用 | 极客快訊</title><meta property="og:title" content="机理综述｜姜黄的生物化学、安全性、药理活性和临床应用 - 极客快訊"><meta property="og:type" content="article"><meta property="og:locale" content="cn"><meta property="og:image" content="https://p3.pstatp.com/large/pgc-image/bca22267bda84c6bac053be9c232e875"><link rel=alternate hreflang=x-default href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%a6/429e687.html><link rel=alternate hreflang=zh-tw href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%a6/429e687.html><link rel=alternate hreflang=zh-cn href=https://geekbank.cf/cn/%e7%a7%91%e5%ad%a6/429e687.html><link rel=alternate hreflang=zh-hk href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%a6/429e687.html><link rel=alternate hreflang=zh-mo href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%a6/429e687.html><link rel=alternate hreflang=zh-my href=https://geekbank.cf/cn/%e7%a7%91%e5%ad%a6/429e687.html><link rel=alternate hreflang=zh-sg href=https://geekbank.cf/cn/%e7%a7%91%e5%ad%a6/429e687.html><link rel=canonical href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%a6/429e687.html><meta property="article:published_time" content="2020-10-29T21:02:34+08:00"><meta property="article:modified_time" content="2020-10-29T21:02:34+08:00"><meta name=Keywords content><meta name=description content="机理综述｜姜黄的生物化学、安全性、药理活性和临床应用"><meta name=author content="极客快訊"><meta property="og:url" content="/cn/%E7%A7%91%E5%AD%A6/429e687.html"><link rel=apple-touch-icon sizes=180x180 href=../../apple-touch-icon.png><link rel=icon type=image/png sizes=32x32 href=../../favicon-32x32.png><link rel=icon type=image/png sizes=16x16 href=../../favicon-16x16.png><link rel=manifest href=../../site.webmanifest><link rel=mask-icon href=../../safari-pinned-tab.svg color=#5bbad5><meta name=msapplication-TileColor content="#ffc40d"><meta name=theme-color content="#ffffff"><link rel=stylesheet href=https://geekbank.cf/css/normalize.css><link rel=stylesheet href=https://geekbank.cf/css/style.css><script type=text/javascript src=https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js></script><script type=text/javascript src=https://geekbank.cf/js/jqthumb.min.js></script><script data-ad-client=ca-pub-3525055026201463 async src=https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js></script></head><body><header id=header class=clearfix><div class=container><div class=col-group><div class=site-name><h1><a id=logo href>🤓 极客快讯 Geek Bank</a></h1><p class=description>为你带来最全的科技知识 🧡</p></div><div><nav id=nav-menu class=clearfix><a class=current href>猜你喜歡</a>
<a href=../../tw/categories/%E7%A7%91%E6%8A%80.html title=科技>科技</a>
<a href=../../tw/categories/%E9%81%8A%E6%88%B2.html title=遊戲>遊戲</a>
<a href=../../tw/categories/%E7%A7%91%E5%AD%B8.html title=科學>科學</a></nav></div></div></div></header><div id=body><div class=container><div class=col-group><div class=col-8 id=main><div class=res-cons><article class=post><header><h1 class=post-title>机理综述｜姜黄的生物化学、安全性、药理活性和临床应用</h1></header><date class="post-meta meta-date">2020-10-29</date><div class=post-meta><span>|</span>
<span class=meta-category><a href=cn/categories/%E7%A7%91%E5%AD%A6.html>科学</a></span></div><div class=post-content><div class=pgc-img><img alt=机理综述｜姜黄的生物化学、安全性、药理活性和临床应用 onerror=errorimg.call(this); src=https://p3.pstatp.com/large/pgc-image/bca22267bda84c6bac053be9c232e875><p class=pgc-img-caption></p></div><p><br></p><p><strong>摘要</strong></p><p>姜黄是一种流行的、天然的且用于治疗多种疾病传统药物。它的根含有不同类型的植物化学物质和矿物质，是最常用的药用部分。这篇综述总结了姜黄的生物化学、安全性、药理活性（机械性）和临床应用方面的最新知识。</p><p>姜黄素被认为是姜黄根茎中的基本成分。姜黄具有多种生物活性，包括抗炎、抗氧化、抗癌、抗诱变、抗微生物、抗肥胖、降血脂、心脏保护和神经保护作用。这些报道的药理活性使姜黄成为进一步临床研究的重要选择。此外，还有关于其安全性和毒性的讨论。</p><p><strong>1.简介</strong></p><p>近几十年来，姜黄是最受欢迎的功能性食品之一。姜黄（Curcuma longa L .; syn .: Curcuma domestica Valeton）属于姜科，在亚洲热带地区广泛种植。</p><p>姜黄作为香料在亚洲国家和全球其他地区的烹饪中具有悠久的历史。全球多个地区使用姜黄及其变种成分来配制某些传统药物来治疗人类疾病，尤其是针对中国，印度，伊朗和印度尼西亚。姜黄长期以来被用作补品。它也可用于多种疾病，包括血脂异常，胃功能紊乱，关节炎，和肝疾病。姜黄素（1,7-双（4-羟基-3-甲氧基苯基）-1E，6E-庚二烯-3,5-二酮或二铁酰甲烷）是衍生自姜黄的多酚。姜黄素可以从植物的根茎中获得。姜黄呈黄色，姜黄素由三种主要的姜黄素复合物组成：姜黄素I，姜黄素II和姜黄素III。姜黄的脱水根部分最多可容纳8％姜黄素。姜黄素不溶于水和乙醚，但具有分散在乙醇和其他有机溶剂中的能力。二铁甲酰甲烷和挥发油是姜黄的其他主要活性成分。姜黄已经提到有许多生物作用，包括抗炎，抗微生物和抗肿瘤活性，抗氧化，和降血脂性能。此外，姜黄也被报道为针对各种癌症的保护剂。</p><p><br></p><p>图1表示有关姜黄的某些重要机制的药用属性的示意图。姜黄素（姜黄的主要活性成分）已被证明是有效的天然药物，可抵抗炎症和氧化过程，因此有可能被用作预防癌症的保护工具。此外，姜黄油含有必需脂肪酸表示抗真菌剂，抗诱变，和抗菌活性。</p><p><br></p><div class=pgc-img><img alt=机理综述｜姜黄的生物化学、安全性、药理活性和临床应用 onerror=errorimg.call(this); src=https://p1.pstatp.com/large/pgc-image/eb83a424486d4a1f83da117e85afa738><p class=pgc-img-caption></p></div><p><strong>图1</strong></p><p>代表姜黄有关某些最重要机制的医学属性的示意图。NF- κ B：核因子κ B; STAT3：信号转导子和转录激活子3；Nrf2：红系衍生的核因子2相关因子2；SOD：超氧化物歧化酶；NFAT：活化的T细胞的核因子；FtsZ：丝状温度敏感突变体Z；GSH：谷胱甘肽；NOS：一氧化氮合酶；ACE：血管紧张素转化酶。</p><p>在当前的审查中，营养价值，姜黄最常用的产品及其生化的简要讨论。此外，人们不仅试图突出姜黄及其成分的抗癌潜力，而且试图通过机理细节，临床应用和姜黄的安全性来讨论其他药理活性。</p><p><strong>2.营养成分</strong></p><p>姜黄是碳水化合物和纤维的丰富来源。此外，它还包含一些蛋白质和脂肪，但其中不含胆固醇。此外，它还含有适量的吡哆醇，维生素C，钾，钙，镁和磷，使其成为营养丰富的天然食品之一。表1显示了姜黄的简要营养成分。</p><p><strong>表1 姜黄的营养成分。</strong></p><p><br></p><p>主要成分</p><p>营养价值（千卡）</p><p>RDA百分比（％）</p><p>能量</p><p>354</p><p>17</p><p>碳水化合物</p><p>64.9</p><p>50</p><p>总脂肪</p><p>9.88</p><p>33</p><p>蛋白</p><p>7.83</p><p>14</p><p>胆固醇</p><p>0</p><p>0</p><p>膳食纤维</p><p>21</p><p>52.5</p><p><strong>维生素</strong></p><p><br></p><p> 吡哆醇</p><p>1.80</p><p>138</p><p> 叶酸</p><p>39</p><p>10</p><p> 烟酸</p><p>5.140</p><p>32</p><p> 核黄素</p><p>0.233</p><p>18岁</p><p> 维生素A</p><p>0</p><p>0</p><p> 维生素C</p><p>25.9</p><p>43</p><p> 维生素E</p><p>3.10</p><p>21</p><p> 维生素K</p><p>13.4</p><p>11</p><p><strong>电解质</strong></p><p><br></p><p> 钾盐</p><p>2525</p><p>54</p><p> 钠</p><p>38</p><p>2.5</p><p><strong>矿物质</strong></p><p><br></p><p> 锰</p><p>7.83</p><p>340</p><p> 钙</p><p>183</p><p>18岁</p><p> 铜</p><p>603</p><p>67</p><p> 铁</p><p>41.42</p><p>517</p><p> 镁</p><p>193</p><p>48</p><p> 磷</p><p>268</p><p>38</p><p> 锌</p><p>4.35</p><p>39.5</p><p><strong>3.主要产品</strong></p><p>表2简要显示了姜黄的广泛使用产品及其简短描述和在日常生活中的用途。</p><p><br></p><p><strong>表2 姜黄的主要产品，其描述和用途。</strong></p><p><br></p><p>产品名称</p><p>描述</p><p>用途</p><p>整个根茎（干燥形式）</p><p>外观：橙棕色，红黄色或浅黄色</p><p>药用目的</p><p>化学成分：可能含有3–15％的姜黄素和1.5至5％的精油</p><p>制备：一般在弱碱性条件下，将手指根茎和母根茎分别煮沸约40-60分钟。随后应进行日晒干燥10–15天，以将水分含量降低约10％</p><p>黄姜粉</p><p>外观：黄色或红黄色</p><p>用作香料，染料，药物和膳食补充剂</p><p>化学成分：主要活性成分（即姜黄素和香精油）在加工过程中以及暴露于光线下可能会减少。必须将粉末包装在防紫外线容器中</p><p>准备：将干燥的手指根茎磨碎以产生其粉末</p><p>姜黄油</p><p>外观：黄色至棕色油</p><p>用作香料，药物和膳食补充剂</p><p>化学成分：叶中的精油通常以单萜类为主。根茎油主要含有倍半萜</p><p>制备：通过蒸汽蒸馏或超临界CO 2提取从干燥的根茎或叶片中提取的提取物</p><p>姜黄油性树脂</p><p>外观：深黄色，红棕色粘稠液体</p><p>用作食用色素，药物和膳食补充剂</p><p>化学成分：它们最多包含25％的精油和37-55％的姜黄素</p><p>制备：通过用有机溶剂（丙酮，二氯甲烷，1,2-二氯乙烷，甲醇，乙醇，异丙醇和轻石油（己烷））进行溶剂萃取或从超临界CO 2萃取中，从干燥的根茎中提取。</p><p>姜黄素</p><p>外观：黄色至橙红色的结晶性粉末</p><p>用作药物和膳食补充剂</p><p>化学成分：姜黄素及其双脱甲氧基和脱甲氧基衍生物的混合物（无固定比例）。三大类姜黄素可能占整个比例的90％。油和树脂可能占少数</p><p>制备：通过从研磨的姜黄根茎中提取溶剂，然后通过结晶过程纯化提取物获得</p><p>用于萃取的有机溶剂为丙酮，二氧化碳，乙醇，乙酸乙酯，己烷，甲醇和异丙醇</p><p><strong>4.分子成分</strong></p><p>姜黄具有许多分子成分，每一种都具有多种生物活性。例如，至少有20种抗生素分子，其中14种具有已知的预防癌症活性。另外，它的12个分子具有抗肿瘤作用，其他12个分子具有抗炎作用。它也包含至少10种具有抗氧化特性的分子成分。总体上，共鉴定出326种姜黄生物活性。姜黄中广泛研究的三个成分是金黄色生物碱姜黄素，即姜黄素，双去甲氧基姜黄素和去甲氧基姜黄素。图2显示姜黄素的天然代谢产物。</p><div class=pgc-img><img alt=机理综述｜姜黄的生物化学、安全性、药理活性和临床应用 onerror=errorimg.call(this); src=https://p3.pstatp.com/large/pgc-image/464a040052e0431487ca6e4e987f9bb8><p class=pgc-img-caption></p></div><div class=pgc-img><img alt=机理综述｜姜黄的生物化学、安全性、药理活性和临床应用 onerror=errorimg.call(this); src=https://p1.pstatp.com/large/pgc-image/a9284328db4744e9bdb406b334063f1d><p class=pgc-img-caption></p></div><p><br></p><p><strong>图2</strong></p><p>姜黄素的2D分子结构：（1）脱甲氧基姜黄素，（2）双去甲氧基姜黄素，（3）姜黄素葡糖苷酸，（4）单去甲基姜黄素，（5）姜黄素单葡萄糖苷，（6）姜黄素二葡萄糖苷，（7）酮姜黄素和（8）烯丙基姜黄素（从开放化学数据库，国家生物技术信息中心和PubChem物质数据库获得和修改；https：//pubchem.ncbi.nlm.nih.gov/substance）。</p><p><strong>5.抗癌</strong><strong>观点</strong></p><p>姜黄很久就用于多种疾病管理。姜黄及其成分可被视为治疗癌症的多目标植物化学物质。例如，细胞凋亡，自噬和细胞周期停滞可能受到其使用的影响。有多种信号传导途径是姜黄素抗癌目标。此外，姜黄可修饰微RNA网络表达的调控。应该注意的是，根据体外和体内研究，姜黄素可抑制组蛋白脱乙酰基酶的活性。</p><p><strong>5.1。大肠癌</strong></p><p>近年来，大肠癌（CRC）已成为令人震惊的普遍卫生保健问题。数据表明，肥胖及其相关的代谢问题与大肠癌的发生有关。已经建立了多种肥胖与CRC进展之间关系的生物学机制。胰岛素抵抗和变更在胰岛素样生长因子-1（IGF-1）有助于肥胖相关结直肠癌发生。还应注意的是，脂肪组织中肿瘤坏死因子-α（TNF-α）的水平升高，这与刺激肿瘤的认可和癌变的发展有关。与肥胖有关的脂肪细胞因子比例失调和慢性炎症增加了CRC的机会。姜黄素可能是预防肥胖个体CRC的一种简便方法。事实上，它刺激AMP活化通过减少COX-2蛋白的外观激酶和阻遏核因子κ B（NF- κ B）对结肠的粘膜动作。姜黄素还降低了血清中的瘦素浓度，反过来增加了脂联素水平。根据另一项研究，泊洛沙姆407可作为聚合物用于结直肠癌治疗中姜黄素类药物的结直肠药物释放系统的扩展。</p><p>姜黄进行抗肿瘤和通过NF-抑制抗癌功能κ乙建立和下调NF- κ与耐力，传播，和癌细胞的转移相关的B相关的基因产物。香料会检查信号转导和转录激活因子3（STAT3）的启动并刺激死亡受体。此外，姜黄改善了活性氧（ROS）的产生并减少了肿瘤细胞系的扩增。此外，姜黄增加了肿瘤细胞对卡培他滨和紫杉醇（化疗药物）的敏感性。它也制服NF- κB激活是由核因子-κB配体（RANKL）的受体激活剂引发的，其可能与破骨细胞生成的抑制有关。因此，姜黄可以通过NF-的抑制有效地阻碍肿瘤细胞的增殖κ B和STAT3途径。此外，姜黄可以成功应对P-糖蛋白介导的CRC多药耐药性的挑战。</p><p><strong>5.2。肾癌</strong></p><p>长期一人肾细胞系暴露于10  μ中号姜黄素改变以剂量依赖的方式溶胀激活的氯电流。姜黄素应用诱导凋亡在人肾细胞，并刺激与放大的音量的细胞亚群的出现在5.0-10的浓度  μ M.同样地，50  μ中号姜黄素发起凋亡及增大结肠直肠腺癌细胞的大小。细胞周期停滞可能是暴露于姜黄素后增加细胞系大小的原因。</p><p><strong>5.3。肝癌</strong></p><p>Yu及其同事研究了人类肝癌SMMC-7721细胞凋亡诱导的分子机制。他们报道姜黄素通过调节bax / bcl-2诱导凋亡，从而明显抑制SMMC-7721细胞的生长。姜黄素似乎靶向纺锤体检查点以启动具有更高浓度的磷酸化细胞分裂周期27（CDC27）的细胞凋亡。CDC27的磷酸化实际上是姜黄素发挥其抗癌作用的机制。姜黄素通过刺激细胞凋亡途径并抑制细胞生长和增殖而导致细胞死亡。</p><p><strong>5.4。骨癌</strong></p><p>丹尼斯和他的同事通过利用天然复合物潘克拉斯汀与姜黄素的合成类似物来治疗骨肉瘤，证明了汞齐治疗的新天性。尽管姜黄素具有很强的抗增殖和抗炎特性，但其低水溶性限制了其用途。一项对照研究描述了使用聚乳酸-乙醇酸共聚物制备和表征纳米姜黄素。似乎提到的纳米颗粒制剂的水溶性和抗肿瘤活性显著提高了。</p><p><strong>5.5。肺癌</strong></p><p>目前，C.longa不仅在体外而且在体内都被标记为拥有抑制肿瘤的装置。已证明姜黄素可促进多西他赛治疗肺癌的肿瘤。同样，姜黄素和多西他赛的同步给药对正常组织以及骨髓和肝脏也有轻微毒性。</p><p><strong>5.6。血液和其他癌症</strong></p><p>另外，姜黄素能够与淋巴瘤细胞一起抑制多种恶性细胞类型的生长。姜黄素与电离辐射（IR）结合治疗Burkitt淋巴瘤细胞系表明，姜黄素的应用可提高淋巴瘤细胞对IR引发的细胞凋亡的敏感性，并改善细胞周期中的G2 / M期阻滞。因此，已经注意到抗凋亡的Bcl-xL细胞周期改变蛋白的下调。发现G2 / M期阻滞（由姜黄素引发）与细胞周期蛋白A，细胞周期蛋白B和细胞周期蛋白依赖性激酶1蛋白表达的明显降低有关。另外，姜黄素诱导的细胞凋亡伴随着Bax蛋白表达的上调和Bcl-2蛋白量的下调而导致线粒体功能障碍。因此，它导致鼻咽癌TW 076细胞中细胞色素c的释放和caspase-9和caspase-3的顺序激活。因此，线粒体和凋亡诱导因子caspase-3依赖性途径似乎是姜黄素对G2 / M期阻滞和细胞凋亡的基本作用。姜黄素也明显降低p65和细胞质I的核易位κ乙α破损。姜黄素预处理会使Survivin和己糖激酶II减少。姜黄素和L-天冬醯胺酶（L-ASP）的联合治疗通过激活半胱氨酸蛋白酶的各种成员（caspase-8和caspase-9 / 3）以及激活I期解毒系统来启动细胞凋亡。姜黄素在患有血液和骨髓癌的患者中与L-ASP协同作用。此外，姜黄素急剧降低耐去势疾病和人平滑肌肉瘤细胞系繁殖和中断通过靶向雷帕霉素途径的AKT-哺乳动物靶标用于沉默子宫平滑肌肉瘤细胞生长。</p><p>大量的姜黄素可减少T细胞，而少量的姜黄素可增强从携带3LL肿瘤的小鼠中提取的T细胞。因此，扩增的CD8 + T细胞显示出IFN- γ释放和增殖的改善，尤其是针对3LL肿瘤细胞。所有的这些结果在肿瘤的成就抑制能力。</p><p>关于姜黄成分对包括MDA-MB-231，MCF-7和HepG2在内的人类癌细胞系的抗增殖作用以及姜黄酮对人血单核细胞的免疫调节作用的研究表明，α-姜黄酮和姜黄素可显著抑制甲状旁腺激素的产生。癌细胞。在应用α-松节油酮和芳族松节油酮后，已经注意到外周血单核细胞的繁殖和细胞因子的组成得到改善。</p><p>如引言中所述，姜黄素具有许多药理特性，但其在水中的溶解度降低限制了其临床应用。因此，将姜黄素制备到纳米载体系统中可增强其渗透到组织中的能力。例如，载有姜黄素的纳米胶囊显著降低了肿瘤体积。</p><p><strong>6.抗氧化和抗炎活性</strong></p><p>近来，由于其抗氧化活性，姜黄受到了特别的关注，其通过直接清除氧自由基并通过核因子类胡萝卜素2相关因子2（Nrf2）激活来刺激抗氧化反应。除了对血管内皮功能和组织及血浆的炎症状态有利的预后外，该特征还表明它潜在地有助于糖尿病性微血管病的治疗。姜黄挥发油中存在的生物活性成分包括据报告对癌变有效的姜黄酮。先前的研究表明，姜黄具有独特的抗氧化潜力。姜黄素去除了姜黄油脂树脂，姜黄油脂树脂是生产姜黄素的原料，并且含有油，树脂和不可提取的姜黄素。在实验室研究中，各种馏分和姜黄油表现出相当大的抗诱变和抗氧化能力。雌性Wistar大鼠的姜黄素浓度为200 mg / kg体重，当其暴露于有机磷农药对硫磷时，可显著降低大鼠海马的氧化损伤。因此，它是防止农药暴露后神经退行性损害的一种替代方法。</p><p>事实上，姜黄保持显著抗炎性能，主要通过的Wnt / β连环蛋白，核因子-κB（NF- κ可能通过髓样分化初级应答88和toll样受体4的堵塞B）（/ NF- κ乙信号和NF-的下调mRNA表达κ B-p65的），和丝裂原活化蛋白激酶途径，并且还通过表观遗传调节作用和氧化还原调节。</p><p>一项系统的综述显示，姜黄素可以通过修饰身体活跃队列中的几种促炎细胞因子（例如TNF - α，IL-6和IL-8）来发挥抗炎作用。在肠炎症的体外模型中也观察到提到的作用。除此之外，姜黄对肠上皮的保护作用对于炎症性肠病患者可能是有前途的。。</p><p>据研究，姜黄素大大降低了胰腺损伤和显著提高PPAR的表达γ。姜黄素的应用导致细胞因子TNF- α释放的调节，这可能是其减轻胰腺损伤的能力的可能依据。姜黄素治疗可能会为患有SCI的人类破译一种新的治疗方法。</p><p>简而言之，存在确凿的科学证据，报告了姜黄及其成分/馏分治疗以氧化和炎症为特征的疾病的功效，因此有必要在饮食方案中使用。</p><p><strong>7.抗菌作用</strong></p><p>姜黄可能是对抗致命细菌感染的另一种抗菌剂。姜黄叶精油的利用显著抑制了真菌的生长以及黄曲霉毒素B1和G1的产生。</p><p>在表没食子儿茶素没食子酸酯（EGCG）存在下，姜黄素对多重耐药性鲍曼不动杆菌的抗菌活性显著提高。EGCG和姜黄素的组合可在医学中用于避免或控制鲍曼不动杆菌感染。</p><p>由于变形虫的包囊使其对抗阿米巴药物不利，因此消除卡氏棘阿米巴（棘阿米巴角膜炎和肉芽肿性阿米巴性脑炎的病因）非常复杂。研究证实了姜黄提取物对棘阿米巴囊肿复制的抑制作用。</p><p>此外，姜黄漱口水可以成功地用作机械斑块管理措施的辅助方法，以预防斑块和牙龈炎。应当指出，姜黄漱口水会导致总微生物数量显著减少。</p><p>姜黄通过抑制FtsZ聚合来抑制丝状温度敏感突变体Z（FtsZ）（细胞骨架蛋白）的组装，从而阻碍了枯草芽孢杆菌和大肠杆菌的生长。</p><p>应当指出，姜黄素作为姜黄的主要成分，具有广泛的抗病毒活性。例如，针对其针对人类免疫缺陷病毒（HIV）的不同机制进行了数项研究。姜黄素已显示抑制HIV-1整合酶。而且，这种多酚及其类似物可以抑制病毒基因的感染和复制。HIV蛋白酶和HIV相关激酶（例如酪氨酸激酶）被它们抑制。此外，姜黄素与生物医学药物具有协同作用。</p><p>应当指出的是，姜黄素抑制嘌呤/脱嘧啶核酸内切酶-1的氧化还原功能。因此，各种各样的基因和途径都受到影响。已经发现姜黄素可以抑制卡波西氏肉瘤相关的疱疹病毒复制，然后控制随后的病理过程（例如，血管生成）。</p><p>关于姜黄生物成分的抗流感活性的研究很多。它可以通过抑制其吸附和复制来抵抗甲型流感病毒（IAV）。而且，姜黄素可以通过抑制IAV感染中局部炎性细胞因子的产物来平衡免疫系统反应。此外，其对NF-调节作用κ在巨噬细胞乙信令。总之，它可以在IAV相关的肺损伤中起到保护和改善作用。</p><p><strong>8.神经保护作用</strong></p><p>据报道，植物来源的成分不仅可以提供神经保护作用，还可以管理与神经退行性疾病症状相关的生化途径，这些疾病包括认知障碍，能量损失/疲劳，情绪变化和焦虑症。此外，它具有神经源性潜力，似乎是通过刺激神经干细胞的增殖和分化来实现的。具有神经保护作用的植物和它们的产品可能是一种新的治疗方法来治疗帕金森氏病（PD）。</p><p>阿尔茨海默氏病（AD）还包括与脑损伤和β-淀粉样蛋白相关的病理相关的慢性炎症反应。研究表明，氧化应激和不良的蛋白质代谢及其相互作用是AD发病机制的核心。姜黄提取物可能是预防AD的潜在来源。AD患者的大脑经历了许多改变（例如，蛋白质合成的干扰，蛋白质剥夺和不平衡的热休克反应（HSR））。HSR负责保护细胞免受各种压力。姜黄素的利用可能是减少与AD有关的氧化损伤和淀粉样蛋白病理的饮食方法。因此，它可能是预防AD的有力工具。</p><p><br></p><p>脑缺血与代表DNA崩解的脑区中TdT介导的dUTP缺口末端标记（TUNEL）阳性细胞的扩增有关。姜黄油治疗可能有助于减少一氧化氮合酶（NOS）亚型，并在脑缺血期间明显减少凋亡细胞的数量。此外，姜黄素可降低脂多糖诱导的趋化因子CCL2 mRNA和蛋白在C6细胞中的表达。水溶性姜黄素制剂（50–200 mg / kg）缩短了平静期，并增强了脑组织中5-羟色胺和多巴胺的水平。结果，这些姜黄素制剂可能为改变神经递质和治疗精神抑郁症提供了新的机会。</p><p>最后，关于姜黄在颅脑外伤中的神经保护作用已有几项研究。结果显示该作用是通过降低氧化应激和脑水肿，BDNF水平升高，保护突触蛋白和线粒体以及激活小胶质细胞而实现的。而且，已经显示它可以降低IL-6，TNF- α，IL- 1β和MCP-1并改善toll样受体4和aquaporin-4的表达。另外，Nrf2途径的激活是有关此作用的最重要机制之一。</p><p><strong>8.1。对代谢综合征，相关疾病和心血管疾病的影响</strong></p><p>关于姜黄素对代谢综合征和相关疾病患者的作用，最近有一些系统的综述。正如荟萃分析的结果所示，与空腹血糖，胰岛素抵抗指数（即HOMA-IR），糖化血红蛋白（即HbA1c），甘油三酸酯，瘦素，脂联素等多种指标相比，总胆固醇，舒张压，体重指数和体重已有显著改善。然而，似乎其消耗与收缩压，低密度脂蛋白胆固醇水平和臀部比率的显著变化无关。应该注意的是，它对高密度脂蛋白胆固醇和腰围的影响存在差异。</p><p>实际上，姜黄提取物的补充通过控制体重，脂肪量，血清脂质和肝脂质发挥抗肥胖作用。此外，蛋白激酶A途径激活的脂解可能是另一种可能的途径。向糖尿病患者补充姜黄素卵磷脂制剂（剂量为1 g /天）表明脚表面皮肤通量减少，微血管病改善，水肿评分瞬时降低和随后的进展在小动脉反应。</p><p>此外，高胆固醇血症受试者体重的100-300 mg / kg剂量的姜黄提取物在血管舒张方面显示出可观的进步。饲喂含有姜黄提取物的饮食的受试者中，包括超氧化物歧化酶和谷胱甘肽过氧化物在内的抗氧化酶的水平也增加了。</p><p>姜黄素类化合物的分离还导致姜黄废油性树脂（SOT），这是报道的对某些健康有益的另一部分。富含姜黄素（17.5％）的SOT可以有效抑制血管紧张素转化酶和低密度脂蛋白的氧化。同样，富含姜黄素的成分可以降低高血压和心血管疾病的风险。</p><p>包括姜黄在内的各种香料在预防和治疗心血管疾病中具有不可避免的作用。调节心脏成纤维细胞的迁徙，增生和肥大途径，肥大信号传导和增殖能力是其心血管保护作用的部分机制。此外，它可以在细胞外基质成分的合成和降解之间取得平衡。</p><p>姜黄用于多种心血管疾病的临床前研究很多，例如心肌梗塞，心力衰竭，心脏肥大，动脉粥样硬化，中风，腹主动脉瘤，药物引起的心脏毒性，心肌病以及与糖尿病相关的心血管问题。另外，有许多关于姜黄素对心血管危险因素疗效的临床试验。</p><p>此外，姜黄和姜黄素对天然和化学试剂引起的心血管毒性具有众所周知的解毒作用。科学报告建议的有益作用在链脲霉素，氨甲喋呤，阿霉素，环孢素A，镉，异丙肾上腺素，过氧化氢，尼古丁，柴油机排气颗粒，叔丁基氢过氧化物，和环磷酰胺毒性。</p><p><strong>9.安全性和毒性</strong></p><p>在许多研究中，通过体外研究，动物研究和临床试验检查了姜黄及其成分的安全性。根据对该主题的全面综述，通过口服途径施用姜黄和姜黄素的标准化粉末/提取物未显示出对动物的显著副作用或毒性。此外，细胞培养研究表明，姜黄素在正常细胞中具有抗增殖作用，并可降低细胞活力。但是，没有关于致突变性和遗传毒性的报道。似乎在人中口服姜黄和姜黄素是安全的，即使是非常规剂量也是如此。在小部分病例中报告有瘙痒，舌头发红，心动过速和胃肠道不适（例如肠胃气胀，腹泻，恶心和便秘）。应当指出，关于口服姜黄素的生物利用度存在若干问题。但是，其静脉内制剂吸收更大。因此，静脉内姜黄素的给药剂量应低于口服。</p><p>应当指出，姜黄素可能引起心血管药物，抗生素，抗抑郁药，化学治疗药物，抗凝剂和抗组胺药的某些药代动力学改变。因此，应谨慎地将其与某些常规药物同时使用。</p><p>根据动物研究，在怀孕期间口服姜黄和姜黄素应被认为是安全的。然而，有报道指出口服姜黄素约1000 mg / kg体重会导致F2代雏鸡的体重增加略有下降。</p><p>关于改善姜黄生物利用度的药物输送技术的应用，应讨论这些现代制剂的安全性。例如，使用载体或表面活性剂作为提高生物利用度的策略可能会导致产品有毒。同样，一些无机金属纳米颗粒（例如金姜黄素纳米颗粒）具有剧毒。</p><p>但是，大多数这些新颖的产品似乎都是安全的。固体脂质姜黄素颗粒制剂对骨肉瘤患者和健康人没有不良影响。聚（N-异丙基丙烯酰胺）输送系统是另一种将姜黄素经鼻输送到大脑的新型系统，没有毒性。姜黄素的二肽纳米颗粒也是安全的。二肽是由氨基酸α，β-脱氢苯丙氨酸和蛋氨酸合成的，它们在自然界中是安全的并且能够分解。新的姜黄素类似物是最近在医学中使用的另一种选择。根据体内研究，他们没有显示出毒性。此外，姜黄素负载的人血清白蛋白纳米颗粒在肿瘤异种移植HCT116模型中静脉内使用时未显示毒性。在某些情况下，姜黄素的现代化配方似乎比传统配方更安全。对新型静脉注射姜黄素的研究结果显示，姜黄素纳米混悬液组的兔子比姜黄素溶液组的小鼠出现局部刺激和静脉炎的风险和红细胞溶血的减少。</p><p><strong>10.结论</strong></p><p>姜黄最广泛使用的部分是其根，其中包含大量的植物化学物质，维生素和矿物质，对治愈各种人类疾病非常有益。姜黄似乎是一种通常安全的药用植物。但是，应严格评估其在妊娠和哺乳期以及肝肾功能衰竭患者中的使用。许多产品是从姜黄中提取的。它的活性最高的成分是姜黄素，其次是其他重要成分，包括姜黄素类Atlantone，二甲氧基姜黄素，二芳基庚烷类，tumerone和类黄酮姜黄素（二氟甲酰甲烷）具有抗菌，消炎和抗氧化特性，可提供针对不同类型的细胞损伤的保护作用。此外，姜黄及其成分不仅提供神经保护作用，还调节帕金森氏病和阿尔茨海默氏病等神经系统疾病的病理。它也已被证明是对抗各种癌症的有效工具。此外，对其抗代谢综合症的作用有一些研究。综上所述，可以得出结论，在饮食方案中建议使用姜黄及其成分以对抗多种疾病。为了更好地理解和判断其在临床实践中的用途，有必要进行进一步的研究。此外，关于其成分的生物利用度和药物递送系统，建议开发现代制剂（例如，纳米粒子，脂质体和微球）并评估其功效。它也已被证明是对抗各种癌症的有效工具。此外，对其抗代谢综合症的作用有一些研究。综上所述，可以得出结论，在饮食方案中建议使用姜黄及其成分以对抗多种疾病。为了更好地理解和判断其在临床实践中的用途，有必要进行进一步的研究。此外，关于其成分的生物利用度和药物递送系统，建议开发现代制剂（例如，纳米粒子，脂质体和微球）并评估其功效。它也已被证明是对抗各种癌症的有效工具。此外，对其抗代谢综合症的作用有一些研究。综上所述，可以得出结论，在饮食方案中建议使用姜黄及其成分以对抗多种疾病。为了更好地理解和判断其在临床实践中的用途，有必要进行进一步的研究。此外，关于其成分的生物利用度和药物递送系统，建议开发现代制剂（例如，纳米粒子，脂质体和微球）并评估其功效。可以得出结论，在饮食方案中建议使用姜黄及其成分来对抗多种疾病。为了更好地理解和判断其在临床实践中的用途，有必要进行进一步的研究。此外，关于其成分的生物利用度和药物递送系统，建议开发现代制剂（例如，纳米粒子，脂质体和微球）并评估其功效。可以得出结论，在饮食方案中建议使用姜黄及其成分来对抗多种疾病。为了更好地理解和判断其在临床实践中的用途，有必要进行进一步的研究。此外，关于其成分的生物利用度和药物递送系统，建议开发现代制剂（例如，纳米粒子，脂质体和微球）并评估其功效。</p><p><br></p><p><strong>资料来源</strong></p><p></p><div class=pgc-img><img alt=机理综述｜姜黄的生物化学、安全性、药理活性和临床应用 onerror=errorimg.call(this); src=https://p3.pstatp.com/large/pgc-image/efb6c34ecaff42269606211f525b9510><p class=pgc-img-caption></p></div><p>ID：doi.org/10.1155/2020/7656919</p><p>发表时间：2020年5月11日</p><p><strong>参考文献</strong></p><p>参考资料（可上下滑动查看）</p><p><br></p><p>1. M. Hajimonfarednejad, M. Ostovar, M. J. Raee, M. H. Hashempur, J. G. Mayer, and M. Heydari, “Cinnamon: a systematic review of adverse events,” Clinical Nutrition, vol. 38, no. 2, pp. 594–602, 2019.View at: Publisher Site | Google Scholar</p><p>2. R. Zare, A. Nadjarzadeh, M. M. Zarshenas, M. Shams, and M. Heydari, “Efficacy of cinnamon in patients with type II diabetes mellitus: a randomized controlled clinical trial,” Clinical Nutrition, vol. 38, no. 2, pp. 549–556, 2019.View at: Publisher Site | Google Scholar</p><p>3. I. Siró, E. Kápolna, B. Kápolna, and A. Lugasi, “Functional food. Product development, marketing and consumer acceptance-A review,” Appetite, vol. 51, no. 3, pp. 456–467, 2008.View at: Publisher Site | Google Scholar</p><p>4. Z. Hajmohammadi, M. Heydari, M. Nimrouzi et al., “Rhus coriaria L. increases serum apolipoprotein-A1 and high-density lipoprotein cholesterol levels: a double-blind placebo-controlled randomized clinical trial,” Journal of Integrative Medicine, vol. 16, no. 1, pp. 45–50, 2018.View at: Publisher Site | Google Scholar</p><p>5. A. Shakeri, M. H. Hashempur, M. Mojibian, F. Aliasl, S. Bioos, and F. Nejatbakhsh, “A comparative study of ranitidine and quince (Cydonia oblonga mill) sauce on gastroesophageal reflux disease (GERD) in pregnancy: a randomised, open-label, active-controlled clinical trial,” Journal of Obstetrics and Gynaecology, vol. 38, no. 7, pp. 1–7, 2018.View at: Publisher Site | Google Scholar</p><p>6. M. H. Hashempur, F. Khademi, M. Rahmanifard, and M. M. Zarshenas, “An evidence-based study on medicinal plants for hemorrhoids in Medieval Persia,” Journal of Evidence-Based Complementary & Alternative Medicine, vol. 22, no. 4, pp. 969–981, 2017.View at: Publisher Site | Google Scholar</p><p>7. T. Tsuda, “Curcumin as a functional food-derived factor: degradation products, metabolites, bioactivity, and future perspectives,” Food & Function, vol. 9, no. 2, pp. 705–714, 2018.View at: Publisher Site | Google Scholar</p><p>8. S. C. Gupta, B. Sung, J. H. Kim, S. Prasad, S. Li, and B. B. Aggarwal, “Multitargeting by turmeric, the golden spice: from kitchen to clinic,” Molecular Nutrition & Food Research, vol. 57, no. 9, pp. 1510–1528, 2013.View at: Publisher Site | Google Scholar</p><p>9. K. P. Nair, The Agronomy and Economy of Turmeric and Ginger: The Invaluable Medicinal Spice Crops, Newnes, London, UK, 2013.</p><p>10. F. Delgado-Vargas and O. Paredes-López, Natural Colorants for Food and Nutraceutical Uses, CRC Press, Boca Raton, FL, USA, 2002.</p><p>11. G. A. F. Hendry and J. Houghton, Natural Food Colorants, Springer Science & Business Media, Berlin, Germany, 1996.</p><p>12. R. F. Tayyem, D. D. Heath, W. K. Al-Delaimy, and C. L. Rock, “Curcumin content of turmeric and curry powders,” Nutrition and Cancer, vol. 55, no. 2, pp. 126–131, 2006.View at: Publisher Site | Google Scholar</p><p>13. C. R. Ireson, D. J. Jones, S. Orr et al., “Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine,” Cancer Epidemiology and Prevention Biomarkers, vol. 11, no. 1, pp. 105–111, 2002.View at: Google Scholar</p><p>14. T.-T. Phan, P. See, S.-T. Lee, and S.-Y. Chan, “Protective effects of curcumin against oxidative damage on skin cells in vitro: its implication for wound healing,” The Journal of Trauma: Injury, Infection, and Critical Care, vol. 51, no. 5, pp. 927–931, 2001.View at: Publisher Site | Google Scholar</p><p>15. A. J. Ruby, G. Kuttan, K. Dinesh Babu, K. N. Rajasekharan, and R. Kuttan, “Anti-tumour and antioxidant activity of natural curcuminoids,” Cancer Letters, vol. 94, no. 1, pp. 79–83, 1995.View at: Publisher Site | Google Scholar</p><p>16. B. B. Aggarwal, A. Kumar, and A. C. Bharti, “Anticancer potential of curcumin: preclinical and clinical studies,” Anticancer Research, vol. 23, no. 1/A, pp. 363–398, 2003.View at: Google Scholar</p><p>17. P. Gul and J. Bakht, “Antimicrobial activity of turmeric extract and its potential use in food industry,” Journal of Food Science and Technology, vol. 52, no. 4, pp. 2272–2279, 2015.View at: Publisher Site | Google Scholar</p><p>18. J. Miquel, A. Bernd, J. M. Sempere, J. Díaz-Alperi, and A. Ramírez, “The curcuma antioxidants: pharmacological effects and prospects for future clinical use. A review,” Archives of Gerontology and Geriatrics, vol. 34, no. 1, pp. 37–46, 2002.View at: Publisher Site | Google Scholar</p><p>19. N. M. K. Selvi, M. Sridhar, R. Swaminathan, and R. Sripradha, “Efficacy of turmeric as adjuvant therapy in type 2 diabetic patients,” Indian Journal of Clinical Biochemistry, vol. 30, no. 2, pp. 180–186, 2015.View at: Google Scholar</p><p>20. R. Srimal, “Turmeric: a brief review of medicinal properties,” Fitoterapia, vol. 68, pp. 483–493, 1997.View at: Google Scholar</p><p>21. D. Mehrabani, M. Farjam, B. Geramizadeh, N. Tanideh, M. Amini, and M. R. Panjehshahin, “The healing effect of curcumin on burn wounds in rat,” World Journal of Plastic Surgery, vol. 4, no. 4, pp. 29–35, 2015.View at: Google Scholar</p><p>22. P. S. Babu and K. Srinivasan, “Hypolipidemic action of curcumin, the active principle of turmeric (Curcuma longa) in streptozotocin induced diabetic rats,” Molecular and Cellular Biochemistry, vol. 166, no. 1-2, pp. 169–175, 1997.View at: Publisher Site | Google Scholar</p><p>23. A. Duvoix, R. Blasius, S. Delhalle et al., “Chemopreventive and therapeutic effects of curcumin,” Cancer Letters, vol. 223, no. 2, pp. 181–190, 2005.View at: Publisher Site | Google Scholar</p><p>24. G. Garcea, D. P. Berry, D. J. Jones et al., “Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences,” Cancer Epidemiology and Prevention Biomarkers, vol. 14, no. 1, pp. 120–125, 2005.View at: Google Scholar</p><p>25. P. R. Holt, S. Katz, and R. Kirshoff, “Curcumin therapy in inflammatory bowel disease: a pilot study,” Digestive Diseases and Sciences, vol. 50, no. 11, pp. 2191–2193, 2005.View at: Publisher Site | Google Scholar</p><p>26. M. Iqbal, S. D. Sharma, Y. Okazaki, M. Fujisawa, and S. Okada, “Dietary supplementation of curcumin enhances antioxidant and phase II metabolizing enzymes in ddY male mice: possible role in protection against chemical carcinogenesis and toxicity,” Pharmacology and Toxicology, vol. 92, no. 1, pp. 33–38, 2003.View at: Publisher Site | Google Scholar</p><p>27. R. A. Sharma, A. J. Gescher, and W. P. Steward, “Curcumin: the story so far,” European Journal of Cancer, vol. 41, no. 13, pp. 1955–1968, 2005.View at: Publisher Site | Google Scholar</p><p>28. G. K. Jayaprakasha, B. S. Jena, P. S. Negi, and K. K. Sakariah, “Evaluation of antioxidant activities and antimutagenicity of turmeric oil: a byproduct from curcumin production,” Zeitschrift für Naturforschung C, vol. 57, no. 9-10, pp. 828–835, 2002.View at: Publisher Site | Google Scholar</p><p>29. A. Y. Leung, Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics, Wiley, Hoboken, NJ, USA, 1980.</p><p>30. K. U. Pradeep, P. Geervani, and B. O. Eggum, “Common Indian spices: nutrient composition, consumption and contribution to dietary value,” Plant Foods for Human Nutrition, vol. 44, no. 2, pp. 137–148, 1993.View at: Publisher Site | Google Scholar</p><p>31. S. Li, W. Yuan, G. Deng, P. Wang, P. Yang, and B. B. Aggarwal, “Chemical composition and product quality control of turmeric (Curcuma longa L.),” Pharmaceutical Crops, vol. 2, no. 1, 2011.View at: Google Scholar</p><p>32. S. Singh, “From exotic spice to modern drug?” Cell, vol. 130, no. 5, pp. 765–768, 2007.View at: Publisher Site | Google Scholar</p><p>33. M. Farjam, D. Mehrabani, F. Abbassnia et al., “The healing effect of Curcuma longa on liver in experimental acute hepatic encephalopathy of rat,” Comparative Clinical Pathology, vol. 23, no. 6, pp. 1669–1673, 2014.View at: Publisher Site | Google Scholar</p><p>34. Y. Zhu and S. Bu, “Curcumin induces autophagy, apoptosis, and cell cycle arrest in human pancreatic cancer cells,” Evidence-Based Complementary and Alternative Medicine, vol. 2017, 2017.View at: Publisher Site | Google Scholar</p><p>35. X. Song, M. Zhang, E. Dai, and Y. Luo, “Molecular targets of curcumin in breast cancer,” Molecular Medicine Reports, vol. 19, no. 1, pp. 23–29, 2019.View at: Google Scholar</p><p>36. P. D. Kasi, R. Tamilselvam, K. Skalicka-Woźniak et al., “Molecular targets of curcumin for cancer therapy: an updated review,” Tumor Biology, vol. 37, no. 10, pp. 13017–13028, 2016.View at: Publisher Site | Google Scholar</p><p>37. H. Mirzaei, A. Masoudifar, A. Sahebkar et al., “MicroRNA: a novel target of curcumin in cancer therapy,” Journal of Cellular Physiology, vol. 233, no. 4, pp. 3004–3015, 2018.View at: Publisher Site | Google Scholar</p><p>38. S. S. Soflaei, A. A. Momtazi-Borojeni, M. Majeed, G. Derosa, P. Maffioli, and A. Sahebkar, “Curcumin: a natural pan-HDAC inhibitor in cancer,” Current Pharmaceutical Design, vol. 24, no. 2, pp. 123–129, 2018.View at: Publisher Site | Google Scholar</p><p>39. M. J. Gunter and M. F. Leitzmann, “Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes,” The Journal of Nutritional Biochemistry, vol. 17, no. 3, pp. 145–156, 2006.View at: Publisher Site | Google Scholar</p><p>40. X.-F. Huang and J.-Z. Chen, “Obesity, the PI3K/Akt signal pathway and colon cancer,” Obesity Reviews, vol. 10, no. 6, pp. 610–616, 2009.View at: Publisher Site | Google Scholar</p><p>41. P. Szlosarek, K. A. Charles, and F. R. Balkwill, “Tumour necrosis factor-α as a tumour promoter,” European Journal of Cancer, vol. 42, no. 6, pp. 745–750, 2006.View at: Publisher Site | Google Scholar</p><p>42. S. Chuengsamarn, S. Rattanamongkolgul, R. Luechapudiporn, C. Phisalaphong, and S. Jirawatnotai, “Curcumin extract for prevention of type 2 diabetes,” Diabetes Care, vol. 35, no. 11, pp. 2121–2127, 2012.View at: Publisher Site | Google Scholar</p><p>43. M.-J. Chen, Y.-M. Cheng, P.-H. Lai, J.-F. Wu, and Y.-C. Hsu, “In vitro biocompatibility of thermally gelling liquid mucoadhesive loaded curcuminoids in colorectal cancer chemoprevention,” International Journal of Colorectal Disease, vol. 27, no. 7, pp. 869–878, 2012.View at: Publisher Site | Google Scholar</p><p>44. K. Troselj and R. Kujundzic, “Curcumin in combined cancer therapy,” Current Pharmaceutical Design, vol. 20, no. 42, pp. 6682–6696, 2014.View at: Publisher Site | Google Scholar</p><p>45. L. Jiménez-Flores, S. López-Briones, M. Macías-Cervantes, J. Ramírez-Emiliano, and V. Pérez-Vázquez, “A PPARγ, NF-κB and AMPK-dependent mechanism may be involved in the beneficial effects of curcumin in the diabetic db/db mice liver,” Molecules, vol. 19, no. 6, pp. 8289–8302, 2014.View at: Publisher Site | Google Scholar</p><p>46. J. H. Kim, S. C. Gupta, B. Park, V. R. Yadav, and B. B. Aggarwal, “Turmeric (Curcuma longa) inhibits inflammatory nuclear factor (NF)-κB and NF-κB-regulated gene products and induces death receptors leading to suppressed proliferation, induced chemosensitization, and suppressed osteoclastogenesis,” Molecular Nutrition & Food Research, vol. 56, no. 3, pp. 454–465, 2012.View at: Publisher Site | Google Scholar</p><p>47. G. Lee, J.-Y. Joung, J.-H. Cho, C.-G. Son, and N. Lee, “Overcoming P-Glycoprotein-Mediated multidrug resistance in colorectal cancer: potential reversal agents among herbal medicines,” Evidence-Based Complementary and Alternative Medicine, vol. 2018, Article ID 3412074, 9 pages, 2018.View at: Publisher Site | Google Scholar</p><p>48. S. Kössler, C. Nofziger, M. Jakab, S. Dossena, and M. Paulmichl, “Curcumin affects cell survival and cell volume regulation in human renal and intestinal cells,” Toxicology, vol. 292, no. 2-3, pp. 123–135, 2012.View at: Publisher Site | Google Scholar</p><p>49. J. Yu, X. Zhou, X. He, M. Dai, and Q. Zhang, “Curcumin induces apoptosis involving bax/bcl-2 in human hepatoma SMMC-7721 cells,” Asian Pac J Cancer Prev, vol. 12, no. 8, pp. 1925–1929, 2011.View at: Google Scholar</p><p>50. S. J. Lee and S. A. Langhans, “Anaphase-promoting complex/cyclosome protein Cdc27 is a target for curcumin-induced cell cycle arrest and apoptosis,” BMC Cancer, vol. 12, no. 1, p. 44, 2012.View at: Publisher Site | Google Scholar</p><p>51. D. Ma, P. Tremblay, K. Mahngar, J. Collins, T. Hudlicky, and S. Pandey, “Selective cytotoxicity against human osteosarcoma cells by a novel synthetic C-1 analogue of 7-deoxypancratistatin is potentiated by curcumin,” PLoS One, vol. 6, no. 12, Article ID e28780, 2011.View at: Publisher Site | Google Scholar</p><p>52. K. L. Nair, A. K. T. Thulasidasan, G. Deepa, R. J. Anto, and G. V. Kumar, “Purely aqueous PLGA nanoparticulate formulations of curcumin exhibit enhanced anticancer activity with dependence on the combination of the carrier,” International Journal of Pharmaceutics, vol. 425, no. 1-2, pp. 44–52, 2012.View at: Publisher Site | Google Scholar</p><p>53. H. Yin, R. Guo, Y. Xu et al., “Synergistic antitumor efficiency of docetaxel and curcumin against lung cancer,” Acta Biochimica et Biophysica Sinica, vol. 44, no. 2, pp. 147–153, 2011.View at: Publisher Site | Google Scholar</p><p>54. Q. Qiao, Y. Jiang, and G. Li, “Curcumin improves the antitumor effect of X-ray irradiation by blocking the NF-κB pathway,” Anti-cancer Drugs, vol. 23, no. 6, pp. 597–605, 2012.View at: Publisher Site | Google Scholar</p><p>55. C. L. Kuo, S. Y. Wu, S. W Ip et al., “Apoptotic death in curcumin-treated NPC-TW 076 human nasopharyngeal carcinoma cells is mediated through the ROS, mitochondrial depolarization and caspase-3-dependent signaling responses,” International Journal of Oncology, vol. 39, no. 39, pp. 319–328, 2011.View at: Publisher Site | Google Scholar</p><p>56. A.-J. Jiang, G. Jiang, L.-T. Li, and J.-N. Zheng, “Curcumin induces apoptosis through mitochondrial pathway and caspases activation in human melanoma cells,” Molecular Biology Reports, vol. 42, no. 1, pp. 267–275, 2015.View at: Publisher Site | Google Scholar</p><p>57. S. A. Shah, S. Prasad, and K. E. Knudsen, “Targeting pioneering factor and hormone receptor cooperative pathways to suppress tumor progression,” Cancer Research, vol. 72, no. 5, pp. 1248–1259, 2012.View at: Publisher Site | Google Scholar</p><p>58. H. Wang, Q.-R. Geng, L. Wang, and Y. Lu, “Curcumin potentiates antitumor activity ofl-asparaginase via inhibition of the AKT signaling pathway in acute lymphoblastic leukemia,” Leukemia & Lymphoma, vol. 53, no. 7, pp. 1376–1382, 2012.View at: Publisher Site | Google Scholar</p><p>59. T. F. Wong, T. Takeda, B. Li et al., “Curcumin disrupts uterine leiomyosarcoma cells through AKT-mTOR pathway inhibition,” Gynecologic Oncology, vol. 122, no. 1, pp. 141–148, 2011.View at: Publisher Site | Google Scholar</p><p>60. F. Han, B. Luo, R. Shi et al., “Curcumin ameliorates rat experimental autoimmune neuritis,” Journal of Neuroscience Research, vol. 92, no. 6, pp. 743–750, 2014.View at: Publisher Site | Google Scholar</p><p>61. F. Luo, X. Song, Y. Zhang, and Y. Chu, “Low-dose curcumin leads to the inhibition of tumor growth via enhancing CTL-mediated antitumor immunity,” International Immunopharmacology, vol. 11, no. 9, pp. 1234–1240, 2011.View at: Publisher Site | Google Scholar</p><p>62. G. G. Yue, B. C. Chan, P.-M. Hon et al., “Evaluation of in vitro anti-proliferative and immunomodulatory activities of compounds isolated from Curcuma longa,” Food and Chemical Toxicology, vol. 48, no. 8-9, pp. 2011–2020, 2010.View at: Publisher Site | Google Scholar</p><p>63. L. Mazzarino, L. F. C. Silva, J. C. Curta et al., “Curcumin-loaded lipid and polymeric nanocapsules stabilized by nonionic surfactants: an in vitro and in vivo antitumor activity on B16-F10 melanoma and macrophage uptake comparative study,” Journal of Biomedical Nanotechnology, vol. 7, no. 3, pp. 406–414, 2011.View at: Publisher Site | Google Scholar</p><p>64. E. Chinedum, E. Kate, C. Sonia, A. Ironkwe, and I. Andrew, “Polyphenolic composition and antioxidant activities of 6 new turmeric (Curcuma longa L.) accessions,” Recent Patents on Food, Nutrition & Agriculture, vol. 7, no. 1, pp. 22–27, 2015.View at: Publisher Site | Google Scholar</p><p>65. A. A. Canales-Aguirre, U. A. Gomez-Pinedo, S. Luquin, M. A. Ramírez-Herrera, M. L. Mendoza-Magaña, and A. Feria-Velasco, “Curcumin protects against the oxidative damage induced by the pesticide parathion in the hippocampus of the rat brain,” Nutritional Neuroscience, vol. 15, no. 2, pp. 62–69, 2012.View at: Publisher Site | Google Scholar</p><p>66. L. Menghini, S. Genovese, F. Epifano, B. Tirillini, C. Ferrante, and L. Leporini, “Antiproliferative, protective and antioxidant effects of artichoke, dandelion, turmeric and rosemary extracts and their formulation,” International Journal of Immunopathology and Pharmacology, vol. 23, no. 2, pp. 601–610, 2010.View at: Publisher Site | Google Scholar</p><p>67. V. H.-C. Liao, C.-W. Yu, Y.-J. Chu, W.-H. Li, Y.-C. Hsieh, and T.-T. Wang, “Curcumin-mediated lifespan extension in Caenorhabditis elegans,” Mechanisms of Ageing and Development, vol. 132, no. 10, pp. 480–487, 2011.View at: Publisher Site | Google Scholar</p><p>68. S. Daniel, J. L. Limson, A. Dairam, G. M. Watkins, and S. Daya, “Through metal binding, curcumin protects against lead- and cadmium-induced lipid peroxidation in rat brain homogenates and against lead-induced tissue damage in rat brain,” Journal of Inorganic Biochemistry, vol. 98, no. 2, pp. 266–275, 2004.View at: Publisher Site | Google Scholar</p><p>69. S. Wei, H. Xu, D. Xia, and R. Zhao, “Curcumin attenuates the effects of transport stress on serum cortisol concentration, hippocampal NO production, and BDNF expression in the pig,” Domestic Animal Endocrinology, vol. 39, no. 4, pp. 231–239, 2010.View at: Publisher Site | Google Scholar</p><p>70. Y. Zhang and Y. Zeng, “Curcumin reduces inflammation in knee osteoarthritis rats through blocking TLR4/MyD88/NF-κB signal pathway,” Drug Development Research, vol. 80, no. 3, pp. 353–359, 2019.View at: Publisher Site | Google Scholar</p><p>71. S. Suresh, P. Sankar, A. G. Telang, M. Kesavan, and S. N. Sarkar, “Nanocurcumin ameliorates Staphylococcus aureus-induced mastitis in mouse by suppressing NF‑κB signaling and inflammation,” International Immunopharmacology, vol. 65, pp. 408–412, 2018.View at: Publisher Site | Google Scholar</p><p>72. C. Li, X. Miao, F. Li et al., “Curcuminoids: implication for inflammation and oxidative stress in cardiovascular diseases,” Phytotherapy Research, vol. 33, no. 5, pp. 1302–1317, 2019.View at: Publisher Site | Google Scholar</p><p>73. H. Yin, Q. Guo, X. Li et al., “Curcumin suppresses IL-1β secretion and prevents inflammation through inhibition of the NLRP3 inflammasome,” The Journal of Immunology, vol. 200, no. 8, pp. 2835–2846, 2018.View at: Publisher Site | Google Scholar</p><p>74. R. Tabrizi, S. Vakili, M. Akbari et al., “The effects of curcumin-containing supplements on biomarkers of inflammation and oxidative stress: a systematic review and meta-analysis of randomized controlled trials,” Phytotherapy Research, vol. 33, no. 2, pp. 253–262, 2019.View at: Publisher Site | Google Scholar</p><p>75. A. Sadeghi, A. Rostamirad, S. Seyyedebrahimi, and R. Meshkani, “Curcumin ameliorates palmitate-induced inflammation in skeletal muscle cells by regulating JNK/NF-kB pathway and ROS production,” Inflammopharmacology, vol. 26, no. 5, pp. 1265–1272, 2018.View at: Publisher Site | Google Scholar</p><p>76. C. Kliem, A. Merling, M. Giaisi, R. Köhler, P. H. Krammer, and M. Li-Weber, “Curcumin suppresses T cell activation by blocking Ca 2+ mobilization and nuclear factor of activated T cells (NFAT) activation,” Journal of Biological Chemistry, vol. 287, no. 13, pp. 10200–10209, 2012.View at: Publisher Site | Google Scholar</p><p>77. D. Fernández-Lázaro, J. Mielgo-Ayuso, J. Seco Calvo, A. Córdova Martínez, A. Caballero García, and C. I. Fernandez-Lazaro, “Modulation of exercise-induced muscle damage, inflammation, and oxidative markers by curcumin supplementation in a physically active population: a systematic review,” Nutrients, vol. 12, no. 2, p. 501, 2020.View at: Publisher Site | Google Scholar</p><p>78. P. Governa, M. Marchi, V. Cocetta et al., “Effects of Boswellia Serrata Roxb. and Curcuma longa L. in an in vitro intestinal inflammation model using immune cells and Caco-2,” Pharmaceuticals, vol. 11, no. 4, p. 126, 2018.View at: Publisher Site | Google Scholar</p><p>79. S. Saraf‐Bank, A. Ahmadi, Z. Paknahad, M. Maracy, and M. Nourian, “Effects of curcumin supplementation on markers of inflammation and oxidative stress among healthy overweight and obese girl adolescents: a randomized placebo‐controlled clinical trial,” Phytotherapy Research, vol. 33, no. 8, pp. 2015–2022, 2019.View at: Google Scholar</p><p>80. F. Samadian, N. Dalili, F. Poor -reza Gholi et al., “Evaluation of Curcumin's effect on inflammation in hemodialysis patients,” Clinical Nutrition ESPEN, vol. 22, pp. 19–23, 2017.View at: Publisher Site | Google Scholar</p><p>81. W. G. Yu, G. Xu, G. J Ren et al., “Preventive action of curcumin in experimental acute pancreatitis in mouse,” The Indian Journal of Medical Research, vol. 134, no. 134, pp. 717–24, 2011.View at: Publisher Site | Google Scholar</p><p>82. Z.-J. Liu, H.-Q. Liu, C. Xiao et al., “Curcumin protects neurons against oxygen-glucose deprivation/reoxygenation-induced injury through activation of peroxisome proliferator-activated receptor-γ function,” Journal of Neuroscience Research, vol. 92, no. 11, pp. 1549–1559, 2014.View at: Publisher Site | Google Scholar</p><p>83. D. R. Ormond, H. Peng, R. Zeman, K. Das, R. Murali, and M. Jhanwar-Uniyal, “Recovery from spinal cord injury using naturally occurring antiinflammatory compound curcumin,” Journal of Neurosurgery: Spine, vol. 16, no. 5, pp. 497–503, 2012.View at: Publisher Site | Google Scholar</p><p>84. K. Sindhu, R. Indra, A. Rajaram, K. J. Sreeram, and R. Rajaram, “Investigations on the interaction of gold-curcumin nanoparticles with human peripheral blood lymphocytes,” Journal of Biomedical Nanotechnology, vol. 7, no. 1, p. 56, 2011.View at: Publisher Site | Google Scholar</p><p>85. R. K. Basniwal, H. S. Buttar, V. Jain, and N. Jain, “Curcumin nanoparticles: preparation, characterization, and antimicrobial study,” Journal of Agricultural and Food Chemistry, vol. 59, no. 5, pp. 2056–2061, 2011.View at: Google Scholar</p><p>86. J. W. Betts and D. W. Wareham, “In vitro activity of curcumin in combination with epigallocatechin gallate (EGCG) versus multidrug-resistant Acinetobacter baumannii,” BMC Microbiology, vol. 14, no. 1, p. 172, 2014.View at: Publisher Site | Google Scholar</p><p>87. N. M. El-Sayed, K. A. Ismail, S. A.-E.-G. Ahmed, and M. H. Hetta, “In vitro amoebicidal activity of ethanol extracts of Arachis hypogaea L., Curcuma longa L. and Pancratium maritimum L. on Acanthamoeba castellanii cysts,” Parasitology Research, vol. 110, no. 5, pp. 1985–1992, 2012.View at: Publisher Site | Google Scholar</p><p>88. P. Waghmare, A. Chaudhari, V. Karhadkar, and A. Jamkhande, “Comparative evaluation of turmeric and chlorhexidinegluconate mouthwash in prevention of plaque formationand gingivitis: a clinical and microbiological study,” The Journal of Contemporary Dental Practice, vol. 12, no. 4, pp. 221–224, 2011.View at: Google Scholar</p><p>89. C. D. Kaur and S. Saraf, “Topical vesicular formulations of Curcuma longa extract on recuperating the ultraviolet radiation-damaged skin,” Journal of Cosmetic Dermatology, vol. 10, no. 4, pp. 260–265, 2011.View at: Publisher Site | Google Scholar</p><p>90. R. E. Khalafalla, U. Müller, M. Shahiduzzaman et al., “Effects of curcumin (diferuloylmethane) on Eimeria tenella sporozoites in vitro,” Parasitology Research, vol. 108, no. 4, pp. 879–886, 2011.View at: Publisher Site | Google Scholar</p><p>91. H. S. Na, M. H. Cha, D.-R. Oh, C.-W. Cho, J. H. Rhee, and Y. R. Kim, “Protective mechanism of curcumin againstVibrio vulnificusinfection,” FEMS Immunology & Medical Microbiology, vol. 63, no. 3, pp. 355–362, 2011.View at: Publisher Site | Google Scholar</p><p>92. S. Zorofchian Moghadamtousi, H. Abdul Kadir, P. Hassandarvish, H. Tajik, S. Abubakar, and K. Zandi, “A review on antibacterial, antiviral, and antifungal activity of curcumin,” BioMed Research International, vol. 2014, 2014.View at: Publisher Site | Google Scholar</p><p>93. E. De Clercq, “Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection,” Medicinal Research Reviews, vol. 20, no. 5, pp. 323–349, 2000.View at: Publisher Site | Google Scholar</p><p>94. S. Prasad and A. K. Tyagi, “Curcumin and its analogues: a potential natural compound against HIV infection and AIDS,” Food & Function, vol. 6, no. 11, pp. 3412–3419, 2015.View at: Publisher Site | Google Scholar</p><p>95. H. Li, C. Zhong, Q. Wang, W. Chen, and Y. Yuan, “Curcumin is an APE1 redox inhibitor and exhibits an antiviral activity against KSHV replication and pathogenesis,” Antiviral Research, vol. 167, pp. 98–103, 2019.View at: Publisher Site | Google Scholar</p><p>96. S. M. Richart, Y.-L. Li, Y. Mizushina et al., “Synergic effect of curcumin and its structural analogue (Monoacetylcurcumin) on anti-influenza virus infection,” Journal of Food and Drug Analysis, vol. 26, no. 3, pp. 1015–1023, 2018.View at: Publisher Site | Google Scholar</p><p>97. J. Dai, L. Gu, Y. Su et al., “Inhibition of curcumin on influenza A virus infection and influenzal pneumonia via oxidative stress, TLR2/4, p38/JNK MAPK and NF-κB pathways,” International Immunopharmacology, vol. 54, pp. 177–187, 2018.View at: Publisher Site | Google Scholar</p><p>98. S. Han, J. Xu, X. Guo, and M. Huang, “Curcumin ameliorates severe influenza pneumonia via attenuating lung injury and regulating macrophage cytokines production,” Clinical and Experimental Pharmacology and Physiology, vol. 45, no. 1, pp. 84–93, 2018.View at: Publisher Site | Google Scholar</p><p>99. S. Heidari, S. Mahdiani, M. Hashemi, and F. Kalalinia, “Recent advances in neurogenic and neuroprotective effects of curcumin through the induction of neural stem cells,” Biotechnology and Applied Biochemistry, 2020.View at: Publisher Site | Google Scholar</p><p>100. R. Kannappan, S. C. Gupta, J. H. Kim, S. Reuter, and B. B. Aggarwal, “Neuroprotection by spice-derived nutraceuticals: you are what you eat!,” Molecular Neurobiology, vol. 44, no. 2, pp. 142–159, 2011.View at: Publisher Site | Google Scholar</p><p>101. R. B. Mythri and M. M. Srinivas Bharath, “Curcumin: a potential neuroprotective agent in Parkinson’s disease,” Current Pharmaceutical Design, vol. 18, no. 1, pp. 91–99, 2012.View at: Publisher Site | Google Scholar</p><p>102. B. Ahmad and L. J. Lapidus, “Curcumin prevents aggregation in α-synuclein by increasing reconfiguration rate,” Journal of Biological Chemistry, vol. 287, no. 12, pp. 9193–9199, 2012.View at: Publisher Site | Google Scholar</p><p>103. H.-F. Ji and L. Shen, “The multiple pharmaceutical potential of curcumin in Parkinson’s disease,” CNS & Neurological Disorders—Drug Targets, vol. 13, no. 2, pp. 369–373, 2014.View at: Publisher Site | Google Scholar</p><p>104. R. B. Mythri, J. Veena, G. Harish, B. S. Shankaranarayana Rao, and M. M. Srinivas Bharath, “Chronic dietary supplementation with turmeric protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-mediated neurotoxicity in vivo: implications for Parkinson's disease,” British Journal of Nutrition, vol. 106, no. 1, pp. 63–72, 2011.View at: Publisher Site | Google Scholar</p><p>105. G. Harish, C. Venkateshappa, R. B. Mythri et al., “Bioconjugates of curcumin display improved protection against glutathione depletion mediated oxidative stress in a dopaminergic neuronal cell line: implications for Parkinson's disease,” Bioorganic & Medicinal Chemistry, vol. 18, no. 7, pp. 2631–2638, 2010.View at: Publisher Site | Google Scholar</p><p>106. R. Wang, Y.-H. Li, Y. Xu et al., “Curcumin produces neuroprotective effects via activating brain-derived neurotrophic factor/TrkB-dependent MAPK and PI-3K cascades in rodent cortical neurons,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 34, no. 1, pp. 147–153, 2010.View at: Publisher Site | Google Scholar</p><p>107. V. Calabrese, D. A. Butterfield, and A. M. Stella, “Nutritional antioxidants and the heme oxygenase pathway of stress tolerance: novel targets for neuroprotection in Alzheimer's disease,” The Italian Journal of Biochemistry, vol. 52, no. 52, pp. 177–181, 2003.View at: Google Scholar</p><p>108. M. Divino da Rocha, F. Pereira Dias Viegas, H. Cristina Campos et al., “The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders II: alzheimers disease,” CNS & Neurological Disorders - Drug Targets, vol. 10, no. 2, pp. 251–270, 2011.View at: Publisher Site | Google Scholar</p><p>109. D. Yanagisawa, N. F. Ibrahim, H. Taguchi et al., “Curcumin derivative with the substitution at C-4 position, but not curcumin, is effective against amyloid pathology in APP/PS1 mice,” Neurobiology of Aging, vol. 36, no. 1, pp. 201–210, 2015.View at: Publisher Site | Google Scholar</p><p>110. S. Doggui, J. K. Sahni, M. Arseneault, L. Dao, and C. Ramassamy, “Neuronal uptake and neuroprotective effect of curcumin-loaded PLGA nanoparticles on the human SK-N-SH cell line,” Journal of Alzheimer's Disease, vol. 30, no. 2, pp. 377–392, 2012.View at: Publisher Site | Google Scholar</p><p>111. P. Dohare, S. Varma, and M. Ray, “Curcuma oil modulates the nitric oxide system response to cerebral ischemia/reperfusion injury,” Nitric Oxide, vol. 19, no. 1, pp. 1–11, 2008.View at: Publisher Site | Google Scholar</p><p>112. Z.-J. Zhang, L.-X. Zhao, D.-L. Cao, X. Zhang, Y.-J. Gao, and C. Xia, “Curcumin inhibits LPS-induced CCL2 expression via JNK pathway in C6 rat astrocytoma cells,” Cellular and Molecular Neurobiology, vol. 32, no. 6, pp. 1003–1010, 2012.View at: Publisher Site | Google Scholar</p><p>113. S. Kulkarni, K. K. Akula, and J. Deshpande, “Evaluation of antidepressant-like activity of novel water-soluble curcumin formulations and St. John’s wort in behavioral paradigms of despair,” Pharmacology, vol. 89, no. 1-2, pp. 83–90, 2012.View at: Publisher Site | Google Scholar</p><p>114. Z. Keshavarzi, F. Shakeri, G. E. Barreto, B. Bibak, T. Sathyapalan, and A. Sahebkar, “Medicinal plants in traumatic brain injury: neuroprotective mechanisms revisited,” BioFactors, vol. 45, no. 4, pp. 517–535, 2019.View at: Publisher Site | Google Scholar</p><p>115. W. Dong, B. Yang, L. Wang et al., “Curcumin plays neuroprotective roles against traumatic brain injury partly via Nrf2 signaling,” Toxicology and Applied Pharmacology, vol. 346, pp. 28–36, 2018.View at: Publisher Site | Google Scholar</p><p>116. M. Akbari, K. B. Lankarani, R. Tabrizi et al., “The effects of curcumin on weight loss among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials,” Frontiers in Pharmacology, vol. 10, 2019.View at: Publisher Site | Google Scholar</p><p>117. M. Azhdari, M. Karandish, and A. Mansoori, “Metabolic benefits of curcumin supplementation in patients with metabolic syndrome: a systematic review and meta‐analysis of randomized controlled trials,” Phytotherapy Research, vol. 33, no. 5, pp. 1289–1301, 2019.View at: Publisher Site | Google Scholar</p><p>118. R. Tabrizi, S. Vakili, K. B. Lankarani et al., “The effects of curcumin on glycemic control and lipid profiles among patients with metabolic syndrome and related disorders: a systematic review and metaanalysis of randomized controlled trials,” Current Pharmaceutical Design, vol. 24, no. 27, pp. 3184–3199, 2018.View at: Publisher Site | Google Scholar</p><p>119. J.-N. Ho, J. Y. Jang, H.-G. Yoon et al., “Anti-obesity effect of a standardised ethanol extract from Curcuma longa L. fermented with Aspergillus oryzae in ob/ob mice and primary mouse adipocytes,” Journal of the Science of Food and Agriculture, vol. 92, no. 9, pp. 1833–1840, 2012.View at: Publisher Site | Google Scholar</p><p>120. G. Appendino, G. Belcaro, U. Cornelli et al., “Potential role of curcumin phytosome (Meriva) in controlling the evolution of diabetic microangiopathy. A pilot study,” Panminerva Medica, vol. 53, no. 3 Suppl 1, pp. 43–49, 2011.View at: Google Scholar</p><p>121. T.-S. Kam, C.-Y. Wong, P.-L. Kwan et al., “Effects and mechanism of turmeric vasorelaxation of the thoracic aorta in hypercholesterolemic rats,” Journal of Medicinal Food, vol. 15, no. 2, pp. 190–199, 2012.View at: Publisher Site | Google Scholar</p><p>122. S. V. Nampoothiri, E. K. Praseetha, V. V. Venugopalan, and A. Nirmala Menon, “Process development for the enrichment of curcuminoids in turmeric spent oleoresin and its inhibitory potential against LDL oxidation and angiotensin-converting enzyme,” International Journal of Food Sciences and Nutrition, vol. 63, no. 6, pp. 696–702, 2012.View at: Publisher Site | Google Scholar</p><p>123. G. Kapakos, V. Youreva, and A. K. Srivastava, “Cardiovascular protection by curcumin: molecular aspects,” Indian Journal of Biochemistry & Biophysics, vol. 49, no. 5, pp. 306–315, 2012.View at: Google Scholar</p><p>124. A. M. Gorabi, S. Hajighasemi, N Kiaie et al., “Anti-fibrotic effects of curcumin and some of its analogues in the heart,” Heart Failure Reviews, 2019.View at: Publisher Site | Google Scholar</p><p>125. P. Y. Liu, “Curcumin: another potential translational candidate for anti-fibrosis on heart failure?” Acta Cardiologica Sinica, vol. 30, no. 5, pp. 483-484, 2014.View at: Google Scholar</p><p>126. H. Li, A. Sureda, H. P. Devkota et al., “Curcumin, the golden spice in treating cardiovascular diseases,” Biotechnology Advances, vol. 38, p. 107343, 2020.View at: Publisher Site | Google Scholar</p><p>127. S. Saraf-Bank, A. Ahmadi, Z. Paknahad, M. Maracy, and M. Nourian, “Effects of curcumin on cardiovascular risk factors in obese and overweight adolescent girls: a randomized clinical trial,” Sao Paulo Medical Journal, vol. 137, no. 5, pp. 414–422, 2019.View at: Publisher Site | Google Scholar</p><p>128. A. Saeidinia, F. Keihanian, A. E. Butler, R. K. Bagheri, S. L. Atkin, and A. Sahebkar, “Curcumin in heart failure: a choice for complementary therapy?” Pharmacological Research, vol. 131, pp. 112–119, 2018.View at: Publisher Site | Google Scholar</p><p>129. T. Farkhondeh and S. Samarghandian, “Antidotal effects of curcumin against agents-induced cardiovascular toxicity,” Cardiovascular & Hematological Disorders-Drug Targets, vol. 16, no. 1, pp. 30–37, 2016.View at: Publisher Site | Google Scholar</p><p>130. A. Hosseini and H. Hosseinzadeh, “Antidotal or protective effects of Curcuma longa (turmeric) and its active ingredient, curcumin, against natural and chemical toxicities: a review,” Biomedicine & Pharmacotherapy, vol. 99, pp. 411–421, 2018.View at: Publisher Site | Google Scholar</p><p>131. V. Soleimani, A. Sahebkar, and H. Hosseinzadeh, “Turmeric (Curcuma longa) and its major constituent (curcumin) as nontoxic and safe substances: review,” Phytotherapy Research, vol. 32, no. 6, pp. 985–995, 2018.View at: Publisher Site | Google Scholar</p><p>132. R. Bahramsoltani, R. Rahimi, and M. H. Farzaei, “Pharmacokinetic interactions of curcuminoids with conventional drugs: a review,” Journal of Ethnopharmacology, vol. 209, pp. 1–12, 2017.View at: Publisher Site | Google Scholar</p><p>133. M. Sun, X. Su, B. Ding et al., “Advances in nanotechnology-based delivery systems for curcumin,” Nanomedicine, vol. 7, no. 7, pp. 1085–1100, 2012.View at: Publisher Site | Google Scholar</p><p>134. V. S. Gota, G. B. Maru, T. G. Soni, T. R. Gandhi, N. Kochar, and M. G. Agarwal, “Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers,” Journal of Agricultural and Food Chemistry, vol. 58, no. 4, pp. 2095–2099, 2010.View at: Publisher Site | Google Scholar</p><p>135. N. Ahmad, I. Ahmad, S. Umar, Z. Iqbal, M. Samim, and F. J. Ahmad, “PNIPAM nanoparticles for targeted and enhanced nose-to-brain delivery of curcuminoids: UPLC/ESI-Q-ToF-MS/MS-based pharmacokinetics and pharmacodynamic evaluation in cerebral ischemia model,” Drug Delivery, vol. 23, no. 7, pp. 2095–2114, 2016.View at: Google Scholar</p><p>136. P. A. Subramani, K. Panati, V. R. Lebaka, D. D. Reddy, and V. R. Narala, “Nanostructures for curcumin delivery: possibilities and challenges,” Nano‐ and Micro‐scale Drug Delivery Systems, Elsevier, Amsterdam, Netherlands, 2017.View at: Google Scholar</p><p>137. H. Ohori, H. Yamakoshi, M. Tomizawa et al., “Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer,” Molecular Cancer Therapeutics, vol. 5, no. 10, pp. 2563–2571, 2006.View at: Publisher Site | Google Scholar</p><p>138. T. H. Kim, H. H. Jiang, Y. S. Youn et al., “Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity,” International Journal of Pharmaceutics, vol. 403, no. 1-2, pp. 285–291, 2011.View at: Publisher Site | Google Scholar</p><p>139. Y. Gao, Z. Li, M. Sun et al., “Preparation and characterization of intravenously injectable curcumin nanosuspension,” Drug Delivery, vol. 18, no. 2, pp. 131–142, 2011.View at: Publisher Site | Google Scholar</p></div><div class="post-meta meta-tags"><ul class=clearfix><li><a>'机理','综述','化学'</a></li></ul></div></article></div></div><div id=secondary><section class=widget><form id=search action=//www.google.com/search method=get accept-charset=utf-8 target=_blank _lpchecked=1><input type=text name=q maxlength=20 placeholder=搜索>
<input type=hidden name=sitesearch value=geekbank.cf>
<button type=submit>🔍</button></form></section><section class=widget><h3 class=widget-title>最新文章 ⚡</h3><ul class=widget-list></ul></section><section class=widget><h3 class=widget-title>其他</h3><ul class=widget-list><li><a href=TOS.html>使用條款</a></li><li><a href=CommentPolicy.html>留言政策</a></li><li><a href=mailto:gdnews@tuta.io rel=nofollow>DMCA</a></li><li><a href=mailto:gdnews@tuta.io rel=nofollow>聯絡我們</a></li></ul></section></div></div></div></div><footer id=footer><div class=container>&copy; 2020 <a href>极客快訊</a></div></footer><script type=text/javascript>window.MathJax={tex2jax:{inlineMath:[['$','$']],processEscapes:true}};</script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js?config=TeX-MML-AM_CHTML" async></script><a id=rocket href=#top></a><script type=text/javascript src=https://kknews.cf/js/totop.js async></script><script type=application/javascript>var doNotTrack=false;if(!doNotTrack){window.ga=window.ga||function(){(ga.q=ga.q||[]).push(arguments)};ga.l=+new Date;ga('create','UA-146415161-2','auto');ga('send','pageview');}</script><script async src=https://www.google-analytics.com/analytics.js></script><script type=text/javascript src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-5e508ed9e4e698bb"></script></body></html>